Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Aylin OZKAN"'
Autor:
Busra Gurel, Melike Berksoz, Eda Capkin, Ayhan Parlar, Meltem Corbacioglu Pala, Aylin Ozkan, Yılmaz Capan, Duygu Emine Daglikoca, Meral Yuce
Publikováno v:
Pharmaceutics, Vol 14, Iss 8, p 1571 (2022)
Avastin® is a humanized recombinant monoclonal antibody used to treat cancer by targeting VEGF-A to inhibit angiogenesis. SIMAB054, an Avastin® biosimilar candidate developed in this study, showed a different charge variant profile than its innovat
Externí odkaz:
https://doaj.org/article/d639b8ba82f649c6b9f86058a8458ef5
Autor:
Aylin Ozkan, Joel Good
Publikováno v:
ASHRAE/IBPSA-USA Building Simulation Conference.
Publikováno v:
Building Research & Information. 47:493-517
In the face of climate change, and as building codes and standards evolve to promote increased building energy efficiency and reduced carbon footprints, it is also important to ensure that building...
Publikováno v:
Building Simulation Conference Proceedings.
Autor:
Büşra Gürel, Eda Çapkın, Ayhan Parlar, Aylin Özkan, Meltem Çorbacıoğlu, Duygu Emine Dağlikoca, Meral Yüce
Publikováno v:
Scientia Pharmaceutica, Vol 90, Iss 2, p 36 (2022)
Bevacizumab is a humanized therapeutic monoclonal antibody used to reduce angiogenesis, a hallmark of cancer, by binding to VEGF-A. Many pharmaceutical companies have developed biosimilars of Bevacizumab in the last decade. The official reports provi
Externí odkaz:
https://doaj.org/article/a00f14c450b247d2a048b9f417756e39